Weight-loss drug craze appears to curb obesity epidemic” ( Dec. 29) is a one-sided article on the pros of obesity drugs without reporting on the negative effects that come with the use of Type 2 ...

Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...

If weight loss were to occur as a side effect of using semaglutide to treat heart disease, that might not always be a good thing. I am talking about for treating older people, who may be severely ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Weight loss drugs like Wegovy, Ozempic, and Mounjaro show transformative effects in obesity, improving heart health and reducing dementia risks. However, studies reveal significant muscle and bone ...

Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Before responding to a recent letter titled "Biden didn't sabotage Harris campaign, uninformed voters did" (Jan. 2), I must ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures ...

I mourn the passing of former President Jimmy Carter and give thanks for his long, good life. Guided by his faith, Carter lived to serve others until the very end. From his commitment to civil ...

Mark Labbett, better known as The Beast from the popular ITV quiz show The Chase, has left fans astounded with his impressive weight loss transformation. The 59-year-old quizmaster, who appeared ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

The only enjoyable part of the evening of the Steelers’ wild card loss was WPXI sports reporter Jenna Harner before and after the game. Whoever hired her should get a huge promotion. She’s ...

Kura Sushi (KRUS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.18 per share a year ago. These figures are ...